Completed PHASE1 INTERVENTIONAL 1-arm NCT01487070

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Sponsor: Retina Institute of Hawaii

Conditions PDR

Interventions Macugen (Pegaptanib Sodium)

Updated 5 times since 2017 Last updated: Dec 5, 2011 Started: Apr 30, 2011 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates PDR and is currently completed. Retina Institute of Hawaii leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Retina Institute of Hawaii

Data source: Retina Institute of Hawaii

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Honolulu, United States